Clinical Trials

Inclusion Criteria:

• Age ≥18 years
• Diagnosis of glioma requiring adjuvant chemotherapy. Patients with GBM; astrocytoma, IDH-mutant; oligodendroglioma IDH-mutant, 1p/19q codeleted are eligible.
• Patients eligible to receive temozolomide as standard of care adjuvant therapy.
• ECOG Performance Status of 0, 1, or 2, AND Karnofsky Performance Status (KPS) of ≥60 (Appendix I)
• Expected survival ≥6 months in the opinion of treatment team
• Willing and able to adhere with the protocol for the duration of the study including undergoing treatment, and attending scheduled visits, and examinations. Participants who do not have devices that will permit telehealth visits will be provided such tablet devices to facilitate appointments for the duration of the study. Participants who do not have financial resources to travel for in-person visits will be provided assistance for cost of travel.
• Negative pregnancy test ≤8 days prior to registration for persons of childbearing potential only.
• Ability to complete patient experience surveys by the participant with or without assistance from their caregiver.

Exclusion Criteria:

• Uncontrolled and/or intercurrent illness or other condition which limits safety of or compliance with study proceedings
• Pregnant or nursing, imprisoned, or lacking capacity for understanding
• Unable to swallow tablets or at risk for impaired absorption of oral medication
• Known hypersensitivity or allergy to temozolomide.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 07/17/2024. Questions regarding updates should be directed to the study team contact.